- August 1, 2018Read more
In a multi-year study of 81 adults, conducted by the Kentucky Neuroscience Institute, the CANS-MCI has been shown to be sensitive to heightened CSF levels of Aβ and tau levels. The study examined cerebrospinal fluid (CSF) amyloid β 1-42 (Aβ) and tau levels and performance on a computerized self-administered test battery, the Computer-Administered Neuropsychological Screen for MCI (CANS-MCI).
- December 7, 2017Read more
The CANS-MCI was developed to solve a problem: there were no tools available that could accurately and economically detect the cognitive changes most predictive of further abnormal decline in adults and the elderly. The most common type of decline in need of early detection was toward Alzheimer’s disease. Therefore the CANS-MCI was based upon a wide array of previous research concerning the changes most predictive of Alzheimer’s.
- November 22, 2017Read more
Although the Internet may appear to give the advantage of availability and ease of access — especially to physically disabled people — the reliability of Internet test results is markedly affected by two detrimental human factors: distractions and coaching. Computer-administered tests should be given by a neutral tester in a controlled environment, preferably a designated quiet room in a medical facility.
- July 17, 2016Read more
265 elderly volunteers were enrolled in a 3-year longitudinal NIA-funded study to test the CANS-MCI for screening test usability in primary care, validity & reliability. Fndings from baseline MCI test screen data were presented.
- June 30, 2016Read more
The CANS-MCI, a computer administered, scored, and interpreted touch screen battery, was evaluated for its ability to screen for mild cognitive impairment. 310 community-dwelling elders enrolled in an NIA-funded study.